If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Zepbound® (tirzepatide) be used in combination with Taltz® (ixekizumab)?
Lilly has not studied the simultaneous use of tirzepatide and ixekizumab in patients with plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or patients with non-radiographic axial spondyloarthritis.
See important safety information, including boxed warning, in the attached prescribing information.
Indication
Tirzepatide
Zepbound is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of
- 30 kg/m2 or greater (obesity) or
- 27 kg/m2 or greater (overweight) with at least 1 weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes [T2D], obstructive sleep apnea, or cardiovascular disease).1
Ixekizumab
Taltz is a humanized interleukin-17A antagonist indicated for the treatment of
- patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
- adults with active psoriatic arthritis
- adults with active ankylosing spondylitis, and
- adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.2
Safety
There are no available safety data on the use of ixekizumab in combination with tirzepatide.3
Contraindications
There are no known contraindications for the concomitant use of ixekizumab with tirzepatide.3
Drug-Drug Interactions
No drug-drug interaction studies have been conducted between ixekizumab and tirzepatide.3
Enclosed Prescribing Information
References
1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
2Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
3Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: January 25, 2024